Pre-pubertal growth in the hyperprostaglandin E syndrome

Area of Science:

• Pediatric Endocrinology
• Nephrology

Background:

• Hyperprostaglandin E syndrome, also known as neonatal Bartter syndrome, is a condition affecting pre-pubertal children.
• Growth patterns in these children are often impacted, necessitating effective therapeutic interventions.

Purpose of the Study:

• To evaluate the long-term effects of indomethacin on the pre-pubertal body growth of children diagnosed with hyperprostaglandin E syndrome.
• To assess catch-up growth and final height achieved during extended indomethacin therapy.

Main Methods:

• Longitudinal follow-up of eight children with hyperprostaglandin E syndrome over 5-12 years.
• Monitoring of height standard deviation scores (SDS), corrected for prematurity, before and during indomethacin treatment.
• Assessment of weight, body mass index, and bone maturation, with correlation analysis against serum potassium and calcium excretion.

Main Results:

• Indomethacin therapy led to significant catch-up growth in the first two years, normalizing height SDS from -2.8 to -0.5.
• Weight, body mass index, and bone maturation reached normal ranges.
• Final height SDS was comparable to target height SDS and similar to other preterm children, irrespective of potassium or calcium levels.

Conclusions:

• Indomethacin treatment facilitates normal long-term skeletal growth in children with hyperprostaglandin E syndrome.
• The growth pattern under indomethacin resembles that of healthy preterm children, indicating therapeutic efficacy.
• Early intervention is crucial for optimal growth outcomes in this condition.